Dilon and GE receive FDA approval for Discovery NM750b breast imaging system

DILON Diagnostics and GE Healthcare are pleased to announce the FDA clearance of the Molecular Breast Imaging (MBI) localization accessory for breast biopsy. The Discovery NM750b and the breast biopsy accessory will be presented at the RSNA conference in Chicago, from November 27 to December 1. The Discovery NM750b will be at the Dilon booth number 6132. This important milestone in the breast imaging segment comes shortly after Dilon and GE signed an exclusive agreement for DILON to distribute GE's Discovery NM750b Molecular Breast Imaging system in North America.

The Discovery NM 750b breast imaging system, designed to measure and image the distribution of selected single photon emission radioisotopes in the human body to aid in the evaluation of lesions, offers clinicians an important tool for imaging of a broad range of patients, including those with dense breast. The MBI localization accessory is a complementary technology to the Discovery NM750b breast imaging system which is designed to accurately locate, in three dimensions, lesions in the breast using information derived from stereotactic pairs of two-dimensional images. It is intended to provide guidance for interventional purposes such as biopsy and pre-surgical.

The power of functional imaging to see and localize early changes is a key factor in early detection of breast cancer.


DILON Diagnostics


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
University of Warwick receives multi-million pound grant to improve healthcare in slums